Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

Houman Sotoudeh; Mohammadreza Alizadeh; Ramin Shahidi; Parnian Shobeiri; Zahra Saadatpour; C. Austin Wheeler; Marissa Natelson Love; Manoj Tanwar

doi:10.3389/fradi.2023.1305390

Frontiers in Radiology (Jan 2024)

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

Houman Sotoudeh,
Mohammadreza Alizadeh,
Ramin Shahidi,
Parnian Shobeiri,
Zahra Saadatpour,
C. Austin Wheeler,
Marissa Natelson Love,
Manoj Tanwar

Affiliations

Houman Sotoudeh: Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States
Mohammadreza Alizadeh: Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
Ramin Shahidi: School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
Parnian Shobeiri: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
Zahra Saadatpour: Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States
C. Austin Wheeler: Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States
Marissa Natelson Love: Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, United States
Manoj Tanwar: Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, United States

DOI: https://doi.org/10.3389/fradi.2023.1305390
Journal volume & issue: Vol. 3

Abstract

Read online

Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification. Recently, AD research has begun to shift focus towards disease-modifying therapies that can alter the progression of AD. In this context, a class of immunotherapy agents known as monoclonal antibodies target diverse cerebral amyloid-beta (Aβ) epitopes to inhibit disease progression. Aducanumab was authorized by the US Food and Drug Administration (FDA) to treat AD on June 7, 2021. Aducanumab has shown promising clinical and biomarker efficacy but is associated with amyloid-related imaging abnormalities (ARIA). Neuroradiologists play a critical role in diagnosing ARIA, necessitating familiarity with this condition. This pictorial review will appraise the radiologic presentation of ARIA in patients on aducanumab.

Published in Frontiers in Radiology

ISSN: 2673-8740 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
Website: https://www.frontiersin.org/journals/radiology

About the journal

Abstract

Keywords